A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally. It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes technologies, such as Enchant and NeuralPLexer to design and develop small molecule therapeutics. Iambic Therapeutics, Inc. was formerly known as Entos, Inc. and changed its name to Iambic Therapeutics, Inc. in May 2023. The company was incorporated in 2019 and is based in San Diego, California.
Financial Summary
| Share Statistics | IAM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $695.4 | $229.3 | 42% |
|
| Shares Out (Mil) | 22.4 | 53.4 | 32% |
|
| Institutional Ownership | na | 92.9% | na |
|
| Float (Mil) | na | 41.4 | na |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 1,554 | 533 | 78% |
|
| Price Change (52-week) |
na | 47.5% | na |
|
| Growth | IAM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | IAM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $18 | $37 | 12% |
|
| Net Income (TTM) (Mil) | ($94) | ($44) | 11% |
|
| EPS (TTM) | ($4.271) | ($1.600) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($66) | ($34) | 8% |
|
| Net Cash Flow (TTM) (Mil) | $9 | $3 | 56% |
|
| Long-Term Debt (Q1) (Mil) | $4 | $4 | 24% |
|
| Enterprise Value (Q1) (Mil) | na | $179 | na |
|
| Valuation | IAM | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.17 | na |
|
| P/E | na | 20.3 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | IAM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (457.5%) | 66.0% | 0% |
|
| Net Margin | (516.4%) | (75.3%) | 2% |
|
| ROA | (79.5%) | (47.1%) | 7% |
|
| ROE | 81.1% | (53.5%) | 95% |
|
| Liabilities to Assets | 31.9% | 29.3% | 23% |
|
| F-Score | na | 2 | na |
|
Iambic Therapeutics, Inc. did not pass any screens on 10/22/2026.
